Biologics company sells shares, registers with SEC

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Meletios Verras)
(Image: Getty/Meletios Verras)

Related tags T cell T cell receptor T cells Biologics SEC Stock exchange Stock IPO phase I

Harpoon offers to sell shares of its common stock in its proposed IPO after registering a statement with the SEC while developing T-Cell engagers.

Harpoon Therapeutics filed a registration statement with the US Securities and Exchange Commission (SEC) in relation to its proposed initial public offering (IPO). Harpoon is currently in a quiet period and was unable to comment on the details of its IPO at this time.

Price and quantity of common stock shares have yet to set.

While Harpoon has registered a statement relating to these securities and it has been filed with the SEC, it has not yet become effective.

The clinical-stage immunotherapy company, specializes in the development of T cell engagers​.

Harpoon is working with CMC Biologics to develop and manufacture​ its three lead biologic candidates: HPN424, HPN536, and HPN217. CMC is using its CHEF1 Expression Platform to create clinical and commercial cell lines for the biologics.

The drug candidates were developed through Harpoon’s Tri-specific T-Cell activating construct (TriTEC) platform. The company has plans on moving HPN424 into Phase I trials through the work being done with CMC Biologics. 

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more